Peptide Pandemonium: Regulatory Capture and the Rise of Unproven Therapies The FDA committee's decision to lift restrictions on the manufacture of peptides for human use is a striking example of regulatory capture.
This move, spearheaded by Health and Human Services Secretary Robert F. Kennedy Jr. , has significant implications for public health and the scientific community.
The controversy surrounding peptide manufacturing stems from a lack of robust evidence regarding their safety and effectiveness.